Inceptionr LLC Sells 2,628 Shares of Biogen Inc. $BIIB

Inceptionr LLC reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 53.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 2,248 shares of the biotechnology company’s stock after selling 2,628 shares during the period. Inceptionr LLC’s holdings in Biogen were worth $412,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of BIIB. Rothschild Investment LLC boosted its holdings in shares of Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after buying an additional 56 shares during the period. Meeder Advisory Services Inc. raised its holdings in Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after acquiring an additional 57 shares during the period. Kera Capital Partners Inc. lifted its position in Biogen by 3.5% during the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 58 shares during the last quarter. Parallel Advisors LLC lifted its position in Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after acquiring an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. boosted its holdings in shares of Biogen by 24.4% during the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 66 shares during the period. 87.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biogen in a research report on Monday, June 22nd. Bank of America reduced their price target on Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research note on Tuesday, July 21st. Guggenheim upped their price objective on Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Canaccord Genuity Group increased their price objective on Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Finally, Wedbush reissued a “neutral” rating and set a $201.00 target price on shares of Biogen in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $220.57.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $202.19 on Monday. The business has a fifty day moving average price of $199.78 and a two-hundred day moving average price of $189.95. The stock has a market capitalization of $29.85 billion, a PE ratio of 21.69 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen Inc. has a fifty-two week low of $124.56 and a fifty-two week high of $219.72.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts predict that Biogen Inc. will post 11.29 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.